Patents Examined by Robert Landsman
  • Method of immunotherapy for treament of human papillomavirus infection
    Patent number: 9333238
    Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: May 10, 2016
    Assignee: IRX Therapeutics, Inc.
    Inventors: James E. Egan, Martin Kast, Harvey Brandwein
  • Composition comprising a mixture of CD95-Fc isoforms and methods of producing same
    Patent number: 9315570
    Abstract: The present invention relates to a composition comprising a mixture of fusion protein isoforms, each fusion protein comprising an extracellular CD95 domain or a functional fragment thereof or an Fc domain or functional fragment thereof, formulations providing such composition in a stable form as well as a method for producing such a composition.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: April 19, 2016
    Assignee: APOGENIX GMBH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Use of gelsolin to diagnose and treat inflammatory diseases
    Patent number: 9316639
    Abstract: The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: April 19, 2016
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Thomas P. Stossel, Teresia Anna Charlotta Magnuson Osborn, Eric Leuchovius
  • Anti-PRLR antibodies and methods for killing PRLR-expressing cells
    Patent number: 9302015
    Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: April 5, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Gavin Thurston, Jessica R. Kirshner, Marcus P. Kelly, Thomas Nittoli, Frank J. Delfino
  • Combination therapy for proliferative disorders
    Patent number: 9295669
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: March 29, 2016
    Assignee: Hoffman La-Roche Inc.
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
  • Method for treating inflammatory conditions with mucosally administered interleukin-2
    Patent number: 9289493
    Abstract: Provided herein are methods for the treatment of abnormal inflammation and inflammatory conditions comprising mucosal administration of an effective amount of an interleukin (e.g. IL-2) or a fragment or derivative thereof. Also provided herein are pharmaceutical compositions for mucosal administration for the treatment of abnormal inflammation and inflammatory conditions, the composition comprising said interleukin or fragment or derivative.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: March 22, 2016
    Assignee: BIOLINGUS IP LLC
    Inventor: Sai Ying Ko
  • Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor
    Patent number: 9290574
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: March 22, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ana Kostic, Ludmila Kelly, Xia Liu, Brendan J. Classon
  • Environmentally sensitive compositions and methods of use in the treatment and diagnosis of tumors
    Patent number: 9289508
    Abstract: An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: March 22, 2016
    Assignees: University of Rhode Island, Yale University
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
  • Diagnosis and treatment of chronic obstructive pulmonary disease (COPD)
    Patent number: 9291626
    Abstract: Provided is a method for diagnosing and/or staging COPD based on detection of one or more histone proteins. In some embodiments, the histone protein is an H3.3 protein comprising a post-translational modification. In some embodiments, the histone protein is H2B, H3, H3.3 or H4. Kits for practicing the methods of diagnosis and/or staging are provided as well. Further provided is a method for treating COPD.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: March 22, 2016
    Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Salim Merali, Camilo Moncada, Steven G. Kelsen, Carlos A. Barrero, Oscar Mauricio Perez Leal
  • B cell activating factor antagonist and preparation method and use thereof
    Patent number: 9290582
    Abstract: The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: March 22, 2016
    Assignees: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD., SICHUAN UNIVERSITY
    Inventors: Li Yang, Yuquan Wei
  • Method of treating pain by administering sublingual fentanyl spray
    Patent number: 9289387
    Abstract: The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: March 22, 2016
    Assignee: INSYS DEVELOPMENT COMPANY, INC.
    Inventors: S. George Kottayil, Venkat R. Goskonda, Zhongyuan Zhu, Linet Kattookaran, Neha Parikh
  • Methods used to characterize and treat glioblastoma
    Patent number: 9283195
    Abstract: The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of TROY. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: March 15, 2016
    Assignee: The Translational Genomics Research Institute
    Inventor: Nhan Tran
  • Methods of producing adalimumab
    Patent number: 9284371
    Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: March 15, 2016
    Assignee: AbbVie Inc.
    Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-Hsiang D. Chang, Thomas Seewoester
  • Methods for preparing an active TNFR-Fc fusion protein
    Patent number: 9279014
    Abstract: The present invention relates to a method for separating and preparing a TNFR-Fc fusion protein using hydrophobic interaction chromatography (HIC). More particularly, the present invention relates to a method for separating and preparing a highly pure active protein from clipped proteins due to displacement effect by adjusting the conductivity of a protein sample using a high concentration of salt solution and by adjusting a loading amount thereof, and a TNFR-Fc fusion protein prepared by the method.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: March 8, 2016
    Assignee: ARES TRADING S.A.
    Inventors: Hye Soon Won, Byung Je Sung, Yong Ho Ahn, Sang Kyung Park
  • Methods of using IL-6R antibodies to block or reduce binding of IL-6 to IL-6R
    Patent number: 9273150
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: March 1, 2016
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
  • Method of screening for an inhibitor of odor cause by furaneol
    Patent number: 9274102
    Abstract: It is intended to identify a substance inhibiting an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone. The present invention provides a method for searching for an inhibitor of an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone, comprising: adding a test substance and 2,5-dimethyl-4-hydroxy-3(2H)-furanone to an olfactory receptor OR5K1 or a polypeptide having at least 80% amino acid sequence identity thereto; measuring the response of the olfactory receptor or the polypeptide to 2,5-dimethyl-4-hydroxy-3(2H)-furanone; and identifying a test substance inhibiting the response of the olfactory receptor or the polypeptide, on the basis of the measured response.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: March 1, 2016
    Assignee: Kao Corporation
    Inventors: Aya Namba, Naoko Saito, Michiaki Inoue, Tsuyoshi Toyabe
  • Interferon lambada-antibody complexes
    Patent number: 9272029
    Abstract: The present invention concerns methods and compositions for forming complexes of interferon-? with an antibody or antigen-binding antibody fragment. In preferred embodiments, the interferon-? and the antibody or fragment are fusion proteins, each comprising a dimerization and docking domain (DDD) moiety from human protein kinase A or an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP). In more preferred embodiments, the interferon-antibody complex is more efficacious for treatment of cancer, asthma, Alzheimer's disease, multiple sclerosis or viral infection than interferon-? alone, antibody alone, or the combination of unconjugated interferon-? and antibody.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 1, 2016
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Donglin Liu
  • Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography
    Patent number: 9266950
    Abstract: Disclosed herein are methods for the isolation and purification of anti-IL-13 antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography (e.g., Protein A affinity chromatography), ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: February 23, 2016
    Assignee: AbbVie Inc.
    Inventor: Robert K. Hickman
  • Methods for modulating D1-D2 dopamine receptor coupling and function
    Patent number: 9266954
    Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: February 23, 2016
    Assignee: Centre for Addiction and Mental Health
    Inventors: Fang Liu, Lin Pei
  • Biomarker for treating cancer patients
    Patent number: 9261512
    Abstract: The present invention concerns biomarkers and use thereof for determining whether a subject is or is not susceptible to developing a prophylactic or therapeutic immune response after such treatment.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: February 16, 2016
    Assignee: Transgene, S.A.
    Inventors: Bruce Acres, Benoit Grellier